


MARCH 7, 2024 • VIRTUAL • COMPLIMENTARY

2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis

Moving the Needle and Controversies
at the Cutting Edge



Memorial Sloan Kettering
Cancer Center

Overview

This didactic and case-based educational program will provide a comprehensive update on the latest advancements in the treatment and research of brain metastasis. Tailored for clinicians and translational scientists, this symposium will cover central nervous system (CNS)-specific outcomes from both molecular and traditional cancer histology viewpoints.

- » Recent evidence for **brain metastasis activity will be highlighted for key medical targets** (e.g. Her2, EGFR, KRAS, CDK, BRAF, and ALK), and leading experts will review brain metastasis prognosis across the cancers commonly resulting in this (lung, breast, and melanoma).
- » A dedicated session on **expanding reach** – at the patient level to those in most need, and on a population level using data science and international collaborations – will review advances in care delivery and clinical trial design and execution.
- » In recognition of the many complex treatment interactions imposed by multimodality treatment often necessary, a **‘Key Controversies’** session will speak to major areas of clinical difficulty, for example, how to distinguish on recurrent disease from radiation necrosis on imaging studies, when to change therapy with CNS-only progressive disease, which leptomeningeal metastasis interventions are currently worthwhile, and special considerations regarding steroid use and radiation therapy for patients requiring immunotherapy.



- » Key scientists will discuss **promising translational and clinical trial approaches** including targeting metastasis-initiating cells and window-of-opportunity studies.
- » Given the special challenge of early detection, a dedicated session will cover **state-of-the art molecular imaging techniques**, the evidence for/against imaging surveillance in standard-risk cancers, and the current state of liquid biopsy.
- » A **roundtable discussion with participants from several centers** will share their experiences and best practices with multidisciplinary team care and discuss areas for improvement. Finally, a multidisciplinary tumor board will review multifaceted cases, highlighting the interplay of various treatment options.

This symposium is set to be an **exclusively live virtual experience** with ample opportunity to network and engage with speakers and other participants.

TARGET AUDIENCE

This symposium is intended for neurosurgeons, radiation oncologists, neurologists and neuro-oncologists, physicians in training, and other allied health professionals who treat and manage patients with metastatic disease.

SYLLABUS

Attendees will receive access to an online syllabus after the symposium, which includes select PDFs of presentations (slides) and video recordings of the lectures.

COMPLIMENTARY REGISTRATION:
msk.org/BrainMetsSymposium

MSK SYMPOSIUM DIRECTORS



Nelson Moss, MD

Co-Director, Multidisciplinary Brain Metastasis Program
Associate Attending
Department of Neurosurgery



Adrienne A. Boire, MD, PhD

Geoffrey Beene Junior Faculty Chair
Associate Attending
Department of Neurology

INVITED SYMPOSIUM FACULTY

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Mark and Mary Stevens Endowed Scholar in Melanoma
Director, Melanoma Program
Director, Solid Tumor Cell Therapy
Stanford University School of Medicine
Stanford, CA

Qing Chen, MD, PhD

Assistant Professor
Immunology Microenvironment & Metastasis
The Wistar Institute
Philadelphia, PA

Professor Rebecca Dent, MD FRCP (Canada)

Deputy Chief Executive Officer (Clinical)
Senior Consultant, Dept of Breast & Gynaecology
Division of Medical Oncology, National Cancer Centre Singapore
Duke-NUS Medical School
Singapore

MITIGATION OF RELEVANT FINANCIAL RELATIONSHIPS

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

Benjamin Ellingson, PhD

Professor and Director of MRI Research
Director, UCLA Brain Tumor Imaging Laboratory
Departments of Radiology, Psychiatry, and Neurosurgery
David Geffen School of Medicine
University of California Los Angeles
Los Angeles, CA

Melanie Hayden Gephart, MD, MAS

Professor of Neurosurgery
Director, Stanford Brain Tumor Center
Stanford, CA

Sarah Goldberg, MD, MPH

Associate Professor of Medicine, Medical Oncology
Division Chief of Thoracic Oncology
Research Director, Center for Thoracic Cancers
Associate Program Director, Medical Oncology-Hematology
Fellowship Program
Yale School of Medicine
New Haven, CT

Priya Kumthekar, MD

Associate Professor of Neurology (Neuro-oncology) and
Medicine (Hematology and Oncology)
Director of the Brain Metastases Program
Northwestern University
Feinberg School of Medicine
Chicago, IL

Emilie Le Rhun, MD, PhD

Attending Physician
University of Zurich
Zurich, Switzerland

Julia Maues

Co-founder
GRASP – Guiding Researchers and Advocates to Scientific Partnerships
Baltimore, MD

Minesh P. Mehta, MD

Deputy Director and Chief of Radiation Oncology
Miami Cancer Institute
Member, Memorial Sloan Kettering Cancer Alliance
Miami, FL

Peter Siegel, PhD

Professor, Department of Medicine
Full Member, Rosalind and Morris Goodman Cancer Institute
Associate Member, Departments of Biochemistry, Anat. &
Cell Biology and Oncology
McGill University
Montreal, Canada

Paul W. Sperduto, MD, MPP, FASTRO

Adjunct Professor
Department of Radiation Oncology
Duke School of Medicine
Durham, NC

Hussein Tawbi, MD, PhD

Deputy Chair, Department of Melanoma Medical Oncology
Co-Director, Andrew M. McDougall Brain Metastasis Clinic & Program
The University of Texas MD Anderson Cancer Center
Houston, TX

Nicole Willmarth, PhD

Chief Mission Officer
American Brain Tumor Association
Chicago, IL

Alexandra Zimmer, MD, MSc

Associate Professor, Hematology & Medical Oncology Division
Breast Cancer Program Director
OHSU, Knight Cancer Institute
Portland, OR

MSK SYMPOSIUM FACULTY**Joshua Budhu, MD, MS, MPH**

Assistant Attending
Nicholls-Biondi Diversity Clinical Scientist Faculty Scholar
Department of Neurology

Robert Daly, MD, MBA

Assistant Attending
Department of Medicine

Alexander Drilon, MD

Chief, Early Drug Development Service
Department of Medicine

Siting Gan, PhD

Postdoctoral Researcher
Department of Cancer Biology and Genetics

Brandon Imber, MD, MA

Assistant Attending
Department of Radiation Oncology

Mark G. Kris, MD

William and Joy Ruane Chair in Thoracic Oncology
Attending
Department of Medicine

Bob T. Li, MD, PhD, MPH

Physician Ambassador to China and Asia-Pacific,
Bobst International Center
Co-Director, Thoracic Liquid Biopsy Program
Chief Scientific Officer, MSK Direct
Associate Attending
Department of Medicine

Shanu Modi, MD

Attending Physician
Department of Medicine

Michael A. Postow, MD

Chief, Melanoma Service
Co-Director, Melanoma Disease Management Team
Department of Medicine

Gregory Riely, MD, PhD

Attending Physician
Vice Chair of Clinical Research
Department of Medicine

Andrew D. Seidman, MD

Attending Physician
Breast Medicine Service
Department of Medicine

Robert J. Young, MD

Director, 3T Neuroradiology Imaging
Attending Radiologist
Neuroradiology Service
Department of Radiology

Schedule

THURSDAY, MARCH 7, 2024

8:00 AM — 5:00 PM EST

- 7:55 AM Attendee Zoom Sign On
- 8:00 AM **Welcome and Introduction**
Nelson Moss, MD

Keynote Address

MODERATOR: Nelson Moss, MD

- 8:05 AM  **Challenges and Successes of Early Drug Development for Brain Metastasis**
Alexander Drilon, MD
- 8:30 AM **The Role of Patient Involvement in Advancing Brain Metastasis Care**
Julia Maues
Patient advocate
- 8:35 AM **Multi-Stakeholder Collaborations to Advance Brain Metastasis Research**
Nicole Willmarth, PhD
American Brain Tumor Association (ABTA)
- 8:40 AM **Q&A and Panel Discussion**

The Changing Prognoses of Brain Metastatic Diseases

MODERATOR: Adrienne A. Boire, MD, PhD

- 8:45 AM **Melanoma Brain Metastases: Successes, Failures, and Future Opportunities**
Michael A. Postow, MD
- 9:00 AM **Lung Cancer Brain Metastases**
Sarah Goldberg, MD, MPH
- 9:15 AM **The Evolution of Brain Metastases in Breast Cancer**
Professor Rebecca Dent, MD FRCP (Canada)
- 9:30 AM **CNS Outcomes with Modern Radiation Approaches**
Minesh P. Mehta, MD
- 9:45 AM **Q&A and Panel Discussion**
- 9:55 AM Break

#MSKBRAINMETSCME

Clinical Trials

MODERATOR: Priya Kumthekar, MD

- 10:05 AM **Clinical Trials Landscape for Leptomeningeal Metastasis**
Priya Kumthekar, MD
- 10:15 AM **Novel Immunotherapy Strategies for Melanoma Brain Metastasis**
Allison Betof Warner, MD, PhD
- 10:30 AM **Window of Opportunity Neurosurgical Trials**
Nelson Moss, MD
- 10:45 AM **Frontiers in Breast Cancer Brain Metastasis: Antibody-drug Conjugate Effectiveness in the CNS**
Shanu Modi, MD
- 11:00 AM **Q&A and Panel Discussion**

Controversies

MODERATOR: Nelson Moss, MD

- 11:10 AM **Treatment Sequencing in Melanoma Brain Metastasis: When Can Local Therapy be Foregone?**
Hussein Tawbi, MD, PhD
- 11:25 AM **CNS Surveillance for Asymptomatic Cancer Patients**
Emilie Le Rhun, MD, PhD
- 11:40 AM **Changing Systemic Therapy Post Oligoprogression in the CNS**
Gregory Riely, MD, PhD
- 11:55 AM **Q&A and Panel Discussion**
- 12:00 PM Lunch Break

Prevention

MODERATOR: Nelson Moss, MD

- 1:00 PM **State-of-the-Art Imaging for Brain Metastasis**
Benjamin Ellingson, PhD
- 1:15 PM **CSF Liquid Biopsy for Brain Metastasis**
Melanie Hayden Gephart, MD, MAS
- 1:30 PM **Chemoprevention of Brain Metastasis**
Alexandra Zimmer, MD, MSc
- 1:45 PM **Q&A and Panel Discussion**

Expanding Reach: From Patient Level to Population Level

MODERATOR: Bob T. Li, MD, PhD, MPH

- 1:50 PM **Collecting and Integrating Multimodal Data**
Paul W. Sperduto, MD, MPP, FASTRO
- 2:05 PM **Innovations in Local Care Delivery for Patients with
Advanced Cancer and Neurologic Impairment**
Robert Daly, MD, MBA
- 2:20 PM **Accelerating Cancer Cures Through International
Clinical Trials R&D**
Bob T. Li, MD, PhD, MPH
- 2:35 PM **Advancing Equitable Care for Patients with Brain
Metastasis**
Joshua Budhu, MD, MS, MPH
- 2:50 PM **Q&A and Panel Discussion**
- 2:55 PM Break

Basic and Translational Science

MODERATOR: Adrienne A. Boire, MD, PhD

- 3:00 PM **Characterizing the Immune Microenvironments
of Brain Metastases**
Peter Siegel, PhD
- 3:15 PM **Distinct Tumor Architectures and Microenvironments for
Brain Metastasis Initiation**
Siting Gan, PhD
- 3:30 PM **Type I IFN Response in Brain Metastasis**
Qing Chen, MD, PhD
- 3:45 PM **Microenvironmental Signals Metabolically Reprogram
Leptomeningeal Cancer Cells**
Adrienne A. Boire, MD, PhD
- 4:00 PM **Q&A and Panel Discussion**
- 4:05 PM **PANEL DISCUSSION**
How to Collaborate Bench-to-Bedside
Priya Kumthekar, MD
Emilie Le Rhun, MD, PhD
Peter Siegel, PhD
Hussein Tawbi, MD, PhD

Multidisciplinary Tumor Board

MODERATOR: Adrienne A. Boire, MD, PhD

4:15 PM Joshua A. Budhu, MD, MS, MPH
Brandon Imber, MD, MA
Mark G. Kris, MD
Nelson Moss, MD
Andrew D. Seidman, MD
Robert J. Young, MD

4:55 PM **Closing Remarks**
Nelson Moss, MD

5:00 PM Adjournment

Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **7.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC RECOGNITION STATEMENTS

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

7.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (**ABIM**) Maintenance of Certification (MOC) program; and

7.75 Lifelong Learning (CME) credits in the American Board of Pathology's (**ABPath**) Continuing Certification program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABPath MOC/CC credit.



We are pleased to extend complimentary registration to all participants for this symposium:

msk.org/BrainMetsSymposium

Please note that **registration is required** in order to participate in this symposium.

This live virtual program will be **delivered using Zoom**. Detailed Zoom access and participation instructions will be provided to registrants prior to the start of the program.

We kindly request that those who register also plan to attend. If you are registered for this symposium and are unable to attend, please notify us by emailing cme@mskcc.org.

Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

For additional details including registration, visit:
msk.org/BrainMetsSymposium



Memorial Sloan Kettering
Cancer Center



Memorial Sloan Kettering
Cancer Center

msk.org/BrainMetsSymposium